Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
MaxCyte ( (MXCT) ) has shared an announcement.
On September 22, 2025, MaxCyte, Inc. announced a workforce reduction plan to streamline operations and improve its cost structure by reducing approximately 34% of its global workforce. This restructuring is expected to result in annualized cost savings of $13.6 million, beginning in the fourth quarter of 2025, and is part of a broader initiative to drive efficient growth and profitability.
The most recent analyst rating on (MXCT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on MaxCyte stock, see the MXCT Stock Forecast page.
Spark’s Take on MXCT Stock
According to Spark, TipRanks’ AI Analyst, MXCT is a Neutral.
MaxCyte’s financial challenges and valuation concerns weigh heavily on the stock’s score. However, strong shareholder support, strategic plans, and a solid cash position provide a basis for potential recovery, especially if operational efficiencies improve and macroeconomic conditions stabilize.
To see Spark’s full report on MXCT stock, click here.
More about MaxCyte
MaxCyte, Inc. is a leading cell-engineering company that focuses on the discovery, development, and commercialization of next-generation cell therapies. It provides platform technologies such as Flow Electroporation® and SeQure DX™ gene editing risk assessment services, enabling precise and scalable cell engineering. The company supports researchers globally in developing safe and effective treatments for human health.
Average Trading Volume: 788,162
Technical Sentiment Signal: Sell
Current Market Cap: $162M
For detailed information about MXCT stock, go to TipRanks’ Stock Analysis page.